As with randomization, if allocation to the study drug is not carried out in accordance with the protocol, the entire study ...

“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

Discover how researchers are overcoming the limitations of the undruggable target in drug discovery using novel approaches ...